- Home
- HIMS vs RDY Comparison
HIMS vs RDY Comparison
Compare HIMS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMS
- RDY
- Stock Information
- Founded
- HIMS 2017
- RDY 1984
- Country
- HIMS United States
- RDY India
- Employees
- HIMS N/A
- RDY N/A
- Industry
- HIMS Medical/Nursing Services
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- HIMS Health Care
- RDY Health Care
- Exchange
- HIMS Nasdaq
- RDY Nasdaq
- Market Cap
- HIMS 10.8B
- RDY 11.6B
- IPO Year
- HIMS N/A
- RDY N/A
- Fundamental
- Price
- HIMS $58.37
- RDY $14.00
- Analyst Decision
- HIMS Hold
- RDY Strong Buy
- Analyst Count
- HIMS 11
- RDY 2
- Target Price
- HIMS $37.20
- RDY $16.95
- AVG Volume (30 Days)
- HIMS 28.9M
- RDY 955.0K
- Earning Date
- HIMS 11-03-2025
- RDY 11-04-2025
- Dividend Yield
- HIMS N/A
- RDY 0.51%
- EPS Growth
- HIMS 866.21
- RDY 2.20
- EPS
- HIMS 0.79
- RDY 0.79
- Revenue
- HIMS $2,013,538,000.00
- RDY $3,897,394,052.00
- Revenue This Year
- HIMS $61.66
- RDY $7.33
- Revenue Next Year
- HIMS $19.48
- RDY $1.96
- P/E Ratio
- HIMS $73.74
- RDY $17.48
- Revenue Growth
- HIMS 88.69
- RDY 15.86
- 52 Week Low
- HIMS $17.36
- RDY $12.26
- 52 Week High
- HIMS $72.98
- RDY $16.17
- Technical
- Relative Strength Index (RSI)
- HIMS 57.55
- RDY 40.98
- Support Level
- HIMS $52.51
- RDY $13.97
- Resistance Level
- HIMS $59.27
- RDY $14.24
- Average True Range (ATR)
- HIMS 3.16
- RDY 0.17
- MACD
- HIMS -0.05
- RDY -0.04
- Stochastic Oscillator
- HIMS 74.57
- RDY 17.78
About HIMS Hims & Hers Health Inc.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.